
Qiagen N.V. was founded in 1986 and is headquartered in Venlo, the Netherlands. Qiagen N.V. provides technologies and products for preanalytical sample preparation and linked molecular assay solutions worldwide. Its sample technologies are used to collect, stabilize, isolate, and purify deoxyribonucleic acid (DNA), ribonucleic acid (RNA), and proteins from blood, bone, and tissue samples; and assay technologies are used to make specific target biomolecules, such as the DNA of a specific virus for subsequent detection and analysis. The company offers sample and assay consumable products that are used in plasmid, DNA purification; RNA purification and stabilization; genomic and viral nucleic acid purification; nucleic acid transfection; polymerase chain reaction (PCR) amplification; reverse transcription; DNA cleanup after PCR and sequencing; and DNA cloning and protein purification. It also provides PCR assays, which allow PCR-based detection of viral, bacterial and parasite, human, and animal pathogens, as well as pharmacogenomic genotyping; and various other products for research in the areas of epigenetics, gene expression, micro RNA, proteomics, RNAi, and applied testing and molecular diagnostics. In addition, the company offers automated systems that provide walk-away automation of sample and assay technologies in low, medium, or high throughput scale, as well as reaction set-up and other laboratory tasks; QIAcube, which allows users in research in life sciences, applied testing, and molecular diagnostic to automate the processing of the company's consumable products; and instruments to OEM partners. Further, it provides custom services, such as whole genome amplification services, DNA sequencing, and non-cGMP DNA production on a contract basis; and sells and/or licenses technology. The company serves researchers at pharmaceutical and biotechnology companies, academic institutions, and government and private laboratories.

Hana Biosciences, Inc. company was founded in 2002 and is based in South San Francisco, California. Hana Biosciences, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing products for the foundation of cancer care. The company develops Optisome encapsulated formulation product candidates and a supportive care product candidate. Optisomal encapsulation is a method of liposomal drug delivery, which is designed to increase tumor targeting and duration of exposure for cell-cycle specific anticancer agents. Its Optisome encapsulated formulation product candidates include Marqibo, a vincristine sulfate liposomes injection for the treatment of adult acute lymphoblastic leukemia and metastatic uveal melanoma; Brakiva, a topotecan liposomes injection for the treatment of solid tumors, including small cell lung cancer and ovarian cancer; and Alocrest, a vinorelbine liposomes injection, which is used in the treatment of non-small cell lung cancer. The company's supportive care product candidate comprises Menadione Topical Lotion, a novel supportive care product candidate for the prevention and/or treatment of the skin toxicities associated with the use of epidermal growth factor receptor inhibitors, which are used in the treatment of lung, colon, head and neck, and pancreatic cancer.

Scios Inc. company, a subsidiary of health care giant Johnson & Johnson, develops treatments targeting cardiovascular disease. Its flagship product Natrecor is an intravenously administered drug approved by the FDA for treating patients with acute heart failure who also experience shortness of breath with minimal activity. When the drug was introduced in 2001, it was the first new treatment for heart failure in more than 14 years. The drug is not without controversy, about both its long-term health effects and the company's marketing of it. Scios maintains the drug is safe and has launched a large clinical trial.

MediGene develops drugs that save lives or just make life easier. Spun off from the Munich Gene Center in 1994, MediGene focuses its R&D efforts on therapies that battle various forms of cancer and autoimmune conditions. It also has several drugs on the market, many of them sold through partnerships with other drug firms. The company's Eligard treatment for prostate cancer is sold in Europe by Astellas Pharma, and its Veregen ointment for genital warts is on the US market (Bradley Pharmaceuticals (now part of Nycomed US) sells the drug). In 2008 MediGene won approval from European regulatory authorities for Oracea, a treatment for rosacea; it sold European marketing rights for the drug to Galderma Laboratories.

Agencourt Biosciences uses more modern weapons to win its battles. The company provides genomic services (including DNA and whole genome sequencing) and nucleic acid purification products that help researchers improve the effectiveness of their drug development process. The company has teamed with a handful of international distributors and marketing partners to get its products into users' hands: These partners include Affymetrix and Life Technologies (formerly Invitrogen). Agencourt Biosciences is a subsidiary of Beckman Coulter.

Amgen GmbH speaks the language of biotech geeks, only with a German accent. Amgen GmbH is a German unit of US-based Amgen, the world's largest biotech company. The subsidiary was established in 1989 to help sell and distribute biotechnical therapies for the treatment of such ailments as chemotherapy side effects, chronic kidney failure, and rheumatoid arthritis. Among the group's products are Epogen and Aranesp, for the treatment of anemia in people with chronic kidney disease; Neupogen and Neulasta, to help restore white blood cell counts for cancer patients; and Enbrel, for the treatment of psoriasis and rheumatoid arthritis.

Marshall Edwards, Inc. was founded in 2000 and is based in North Ryde, Australia. Marshall Edwards, Inc. is a subsidiary of Novogen Limited. Marshall Edwards, Inc., a developmental stage pharmaceutical company, engages in the development and commercialization of drugs for the treatment of cancer in the United States and Australia. The company involves in the clinical development and commercialization of its phenoxodiol drug candidates for the treatment of cancer; triphendiol, a signal transduction inhibitor for the treatment of pancreas and bile duct cancers, and melanoma; NV-143, an investigational anti-cancer drug to sensitize melanoma cell lines to the standard of care drug, dacarbazine, and members of the platinum drug family; and NV-128, an investigational cancer compound to promote cancer cell death by targeting the specific protein regulatory pathway in ovarian cancer cells. It is also conducting a Phase II prostate cancer clinical trial using phenoxodiol.

ROHTO Pharmaceutical Co., Ltd. company was founded by Yasutami Yamada in 1899 as Shintendo Yamada Anmin Pharmacy. Later, it changed its name to Rohto Pharmaceutical Co., Ltd. in 1949. Rohto Pharmaceutical is headquartered in Osaka, Japan. Rohto Pharmaceutical Co., Ltd. engages in the manufacture and marketing of pharmaceutical and other healthcare products in Japan and internationally. It primarily offers eye care, skin care, and oral medicine and supplement products. The company's eye care products include eye drops, eye wash preparations, and contact lens care products. Its eye care products spreads moisture over the surface of the eyes, suppresses allergy and works on ocular itching, as well as are used for the treatment of sties and conjunctivitis, inflammation or itching caused by bacteria on lenses, and eye disease causing pollens and house dust.Rohto company's skin care products include dermal medicines, which are used for the treatment of dry skin and females' anorectal discomforts; lip care products that are used for the prevention of dry, sore, and roughness of lips; and hand, body, sun, and acne care products. Rohto Pharmaceutical's oral medicine and supplement products include `Pansion' brand products, which are primarily used for the treatment of gastric discomfort, mucosal repair agents and stomachics for improving damaged gastric mucosa, stomach pain, and heartburn and other hyperacidity-related symptoms. It also offers a range of test products, including blood sugar testing kits, ovulation self-test kits, and pregnancy self-test kits; and denture cleansers.

Laboratorios Almirall can help patients with a lot of ailments. The pharmaceutical company develops, manufactures, and markets drugs for a wide range of conditions affecting the digestive, central nervous, respiratory, and cardiovascular systems. Products include ebastine (antihistamine), aceclofenac (anti-inflammatory), and almotriptan (anti-migraine drug). The company, which is the leading drugmaker in Spain, operates from offices in Europe and Mexico and markets its drugs in more than 70 countries. Laboratorios Almirall is currently focusing its research efforts on treating asthma, chronic obstructive pulmonary disease, rheumatoid arthritis, and dermatological problems, among others.

Microbix makes biotherapeutic drugs, vaccines, and infectious disease diagnostics for multinational manufacturers. The company's pipeline includes leading generic drug candidate ThromboClear for the treatment of coronary artery thrombosis and the FDA-approved drug urokinase, used to treat pulmonary embolism. Microbix has also submitted patents for its Sperm Sexing Technology, which enables livestock producers to predetermine offspring gender prior to conception. In 2008 Microbix entered into an agreement with China to build one of the world's largest influenza manufacturing plants to produce flu vaccines.
Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.







.webp)
.webp)
.webp)
.webp)
.webp)






